Stem Cells Coming Back From Brink of Funding Bans (GERN, STEM, ASTM, CYTX, NBS, ISCO, BTIM)

September 9, 2010 · Filed Under Financial, stem cells · Comment 

The Department of Justice, the White House, and many other activists have been steadily trading to get the ban lifted on the stem cell funding that surprised the entire biotech, drug, and stem cell research community.  Now it seems that a U.S. District Court has suspended that ban on state-funded embryonic stem cell research.

Geron Corporation (NASDAQ: GERN) is now up 9% at $5.34 versus a 52-week trading range of $4.37 to $7.51.  Geron recently received an FDA lifting of a clinical trial hold involving spinal cord injuries.

StemCells Inc. (NASDAQ: STEM) is up 7% at $0.83 versus a 52-week range of $0.75 to $1.79.  This one recently had positive paralysis study data and our indications were that much or all of the operations here were not really going to be hurt or hit from the funding bans.

Aastrom Biosciences, Inc. (NASDAQ: ASTM) is up 2.7% at $1.52 versus a 52-week range of $1.32 to $4.16.

Cytori Therapeutics, Inc. (NASDAQ: CYTX) is up 4.8% at $4.86 and the 52-week range is $2.93 to $9.50.

Neostem, Inc. (AMEX: NBS) is up 2.3% at $1.77 versus a 52-week trading range of $1.26 to $3.50.  As we have outlined before, NeoStem is actually tied to adult stem cells rather than embryonic stem cells.

International Stem Cell Corporation (ISCO.OB) is one that had a pending funding of $10 million back in July.

BioTime, Inc. (NASDAQ: BTIM) is down 5.2% at $4.56 versus a 52-week range of $3.02 to $8.42.  BioTime recently noted that a peer reviewed Regenerative Medicine publication showed that the aging of human cells can be reversed.

JON C. OGG

Stem Cells To Skin Rejuvenation (ISCO)

April 21, 2009 · Filed Under General · Comments Off 

International Stem Cell Corporation (OTCBB: ISCO) announced that it has received “excellent preliminary results” for a new retail skin rejuvenation product.  It also noted that this was developed as a result of its fundamental research into Parthenogenic Stem Cells of a proprietary combination of the special growth media for human skin tissue created by the company.  The product coupled with the by-products of the production of Parthenogenic Stem Cells, appears to have a dramatic impact on the restoration and retention of skin moisture.

The company is also claiming that the product may have longer term benefits for skin rejuvenation.  Further testing is to be conducted to confirm this preliminary data. If subsequent research supports the promising initial results, the Company plans to launch a new line of skin rejuvenation products based on this discovery.

The company called this as showing the early signs of being a significant breakthrough in providing an oil free skin moisturizing product, and one that might also provide long term benefits in reducing wrinkles and other visible signs of the natural aging process.

This is an OTC Bulltin Board stock, so as always keep in mind that filing requirements can be different and trade data may be delayed.  It is also in penny stock land.

Jon C. Ogg

    Subscribe to BioHealth Investor BioHealth Investor RSS Feed